New research demonstrates the ability of ADDomer™ to tackle viral infections
29 November 2023
New research has demonstrated the potential for the ADDomer ™ platform to produce thermostable vaccines and reagents to tackle viral infections The study led by the University of Bristol and Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer platform, is published in Antibody Therapeutics today [29 November].
The research team explored the innovative technology behind the development of an ADDomer vaccine targeting severe acute respiratory syndrome COVID-19 (SARS-CoV-2).
The study, using an integrated approach, combined synthetic, computational and structural methods with in vitro antibody selection and in vivo immunisation to design, produce and validate nature-inspired nanoparticle-based vaccines and reagents.
The research demonstrates the use of Imophoron’s patented multivalent nanoparticle superbinder technology against SARS-CoV-2, including immune-evasive variants of concern.
Imre Berger, Professor of Biochemistry and Director of the Max Planck-Bristol Centre for Minimal Biology at the University of Bristol, and co-author on the paper, said: "COVID-19 reminds us of the critical importance of being prepared for the next pandemic, requiring innovative approaches to help and speed up reagent and vaccine development against emerging threats.
"Our study demonstrates the use of ADDomer-based nanoparticles in active and passive immunisation and provides a blueprint for developing reagents and vaccines to tackle respiratory viral infections."
Richard Bungay, Chief Executive of Imophoron, commented: "This important paper highlights Imophoron’s unique ADDomer and Gigabody technology platforms and their significant potential in developing novel, thermostable vaccines to combat infectious diseases.
"The research represents a significant milestone for our team of world-class scientists, in collaboration with the excellent team at the University of Bristol, in our ongoing commitment to advancing global health."
'In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2' by Imre Berger et al. in Antibody Therapeutics [open access]
Imophoron was founded in 2017 and has developed a thermostable nanoparticle platform, ADDomer, a disruptive technology for the development of vaccines. The ADDomer platform is focused initially on the development of vaccines to combat present and future infectious diseases, and also has significant potential to treat diseases with high unmet needs such as oncology. The ADDomer platform is based on a self-assembling thermotolerant protein that permits rapid insertion of large numbers of epitopes in a single particle. Imophoron is building a pipeline of thermostable, nanoparticle ADDomer vaccines, including multivalent approaches, to address critical medical challenges that impact communities worldwide.
Imophoron has also developed a novel nanobody platform, Gigabody, which has broad range of potential applications across multiple therapeutic areas.